The multi-omics analyses and sufficient in vivo/vitro experiments shed light on PIM/PI3K/mTOR inhibition as a promising combinatorial therapeutic strategy to improve clinical outcomes in NB. This evidence concerns the gene MTOR and neuroblastoma.